Home / Market News / $RZLT
benzinga Corporate Catalyst Impact 65/100 ● positive

FDA Recommends Meeting for Rezolute Drug for Rare Blood Sugar Disorder Despite Missed Endpoints

Oct 5, 2026, 3:53 PM UTC · Primary ticker $RZLT

Rezolute Inc. announced that the FDA recommended a pre-Biologics License Application (BLA) meeting for its drug ersodetug, despite the Phase 3 sunRIZE study missing its primary and key secondary endpoints. This recommendation, based on a re-evaluation of continuous glucose monitoring (CGM) data, suggests a potential path forward for the drug's approval, offering a glimmer of hope after initial trial failures.

Rezolute's drug, ersodetug, for congenital hyperinsulinism, initially failed its Phase 3 trial by missing primary and key secondary endpoints based on finger-stick measurements. However, the FDA, after reviewing continuous glucose monitoring (CGM) data and acknowledging challenges with traditional measurements in this patient population, has recommended a pre-BLA meeting. This is a significant development as it reopens a potential pathway for regulatory approval, which was previously in doubt. For traders, this creates a short-term opportunity for RZLT as the stock initially reacted positively before pulling back, indicating market uncertainty but also renewed hope. Long-term implications depend on the outcome of the pre-BLA meeting and the formal BLA review, as well as upcoming results from the upLIFT study for tumor HI, which could further strengthen their submission strategy.

$RZLT positive FDA recommendation for pre-BLA meeting despite missed endpoints
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.